Synthesis of some novel 2-substituted benzoxazoles as anticancer, antifungal, and antimicrobial agents

Arpaci T, Sener A, Yalcin I, Altanlar N (2002) Synthesis and antimicrobial activity of some 2-[p-substituted-phenyl]benzoxazol-5-yl-arylcarboxyamides. Arch Pharm (WeinHeim) 335:283–288

Arpaci T, Oeren I, Altanlar N (2002) Synthesis and antimicrobial activity of some novel 2-(p-substituted-phenyl)-5-substituted-carbonylaminobenzoxazoles. IL Farmaco 57:175–181

Arpaci T, Sener A, Yalcin I, Altanlar N (2002) Synthesis and microbiological activity of some novel N-[2-(p-substitutedphenyl)-5-benzoxazolyl]-cyclohexyl carboxamide, -cyclohexyl acetamide and -cyclohexyl propionamide derivatives. IL Farmaco 57:771–775

Balani SK, Pitzenberger SM, Kauffman LR, Arison BH, Ramjit HG, Goldman ME, O’Brien JA, King JD, Hoffman JM, Rooney CS, Theoharides AD (1992) Metabolism of a new HIV-1 reverse transcriptase inhibitor, 3-[2- (benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one (L-696,229), in rat and liver slices. Drug Metab Dispos 20:869–876

Bartsch H, Erker T (1991) Chemistry of O,N- and S,N-heterocycles, X: Synthesis and biological activity of 2-substituted 2-ethylbenzoxazoles. Arch Pharm 324:79–82

Cheng CC, Liu DE, Chou TC (1993) Design of antineoplastic agents on the basis of the “2-phenyl naphthalene-type” structural patterns. Heterocycles 35:775–789

Dumez E, Snaith JS, Jackson REW, Mc Elroy AB, Overington J, Wythes MJ (2002) Synthesis of macrocyclic, potential protease inhibitors using a generic scaffold. J Org Chem 67:4882–4892

Easmon J, Puerstinger G, Roth T, Fiebg HH, Jenny M, Heinisch G, Hofmann J (2001) 2-benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: Anovel class of antitumour agents. Int J Cancer 94:89–96

Ersan S, Nacak S, Berkem R, Ozden T (1997) Synthesis and antimicrobial activities of 2-[(α-methylbenzylidene)-hydrazeno]benzoxazoles. Arzneim Forsch 47:963–965

Hall IH, Peaty NJ, Henry JR, Easmon J, Heinisch G, Purshinger G (1999) Investigation on the mechanism of action of the novel anti tumor agents 2-benzothiazolyl, 2benzoxazolyl, and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine. Arch Pharm (Weinheim) 332:115–123

Haskell CM (2001) Introduction, In Cancer treatment, 5th ed., Chapter 1, Saunders,W.B., Philadelphia. Chapter 1

Hoffman JM, Smith AM, Rooney CS, Fisher TE, Wai JS, Thomas CM, Bamberger DL, Barnes JL, Williams TM, Jones JH, Olson BD, O’Brien JA, Goldman ME, Nunberg JH, Quintero JC, Schleif WA, Emini EA, Anderson PS (1993) Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 4. 3-[2-(Benzoxazol-2-yl)ethyl]-5-ethyl-6-methylpyridin-2(1H)-one and analogs. J Med Chem 36:953–966

Kim JS, Sun Q, Gatto B, Yu C, Liu LE, LoVoie EJ (1996) Structure-activity relationships of benzimidazoles and related heterocycles as topoisomerase I poisons. Bioorg Med Chem 4:621–630

Kumar D, Jacob MR, Reynolds MB, Kerwin SM, (2002) synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. Bioorg Med Chem 10:3997–4004

Michel KH, Boeck LD, Hoehn MM, Jones ND, Chaney MO (1984) The discovery, fermentation, isolation and structure of antibiotics A33853 and its tetraacetyl derivatives. J Antibiot 37:441–445

Olsen DB, Carroll SS, Culberson JC, Shafer JA, Kuo LC (1994) Effect of template secondary structure on the inhibition of HIV-1 reverse transcriptase by a pyridinone non-nucleoside inhibitor. Nucleic Acids Res 22:1437–1443

Oren I, Temiz O, Yalcin I, Sener E, Akin A, Ucarturk N (1997) Synthesis and antimicrobial activity of 5 (or 6) –methyl-2-substituted benzoxazoles and benzimidazole derivatives. Arzneim Forsch 47:1393–1400

Perrin L, Rakik A, Yearly S, Baumberger C, Kinloch-de- Loies S, Pechiere M, Hirschel B (1996) Combined therapy with Zidovudine and L-697,661 in primary HIV infection. AIDS 10:1233–1237

Prudhomme M, Guyat J, Jeminet G (1986) Semisynthesis of A23187(calcimycin) analogues. II Introduction of a methyl group on the benzoxazole ring. J Antibiotics 39:934–937

Reiner R (1982) An Introduction to Antibiotics. Georg Thiem Verlag, Stuttgart–New York., pp. 151

Saari WS, Wai JS, Fisher TE, Thomas CM, Hoffman JM, Rooney CS, Smith AM, Jones JH, Bamberger DL, Goldman ME, O’Brien JA, Nunberg JH, Quintero JC, Schleif WA, Emini EA, Anderson PS (1992) Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogs of 3-aminopyridin-2(1H)-one. J Med Chem 35:3792–3802

Sener E, Yalcin I, Temiz O, Oren I, Akin A, Ucarturk N (1997) synthesis & structural activity relationships of some 2,5-disubstituted benzoxazoles & benzimidazoles as antimicrobial agents. IL Farmaco 52:99–103

Shi D, Bradshaw TD, Wrigley S, McCall CJ, Leieveld P, Fichtner I, Stevens MFG (1996) Antitumor benzothiazoles. 3.1 Synthesis of 2-(4aAminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem 39:3375–3384

Staszewski S, Massari FE, Kaber A, Gohler R, Durrr S, Anderson KW, Schneider CL, Waterbury JA, Bakshi KK, Taylor VI, Hildebrand CS, Kriesl C, Haffstedt B, Schleif WA, Byrnes VW (1995) Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J Infect Dis 171:1159–1165

Temiz O, Oren I, Sener E, Ucarturk N (1998) Synthesis and microbiological activity of some novel 5- or 6-methyl-2-(2,4-disubstituted phenyl) benzoxazole derivatives. IL Farmaco 53:337–341

Ueki M, Ueno K, Miyadoh S, Shibata K, Taniguchi M, Oi SJ (1993) UK-1, a novel cytotoxic metabolite from streptomyces sp. 517–02.I. Taxonomy, fermentation, isolation, physicochemical and biological properties. Antibiotics 46:1089–1094

Yalcin I, Oren I, Akin A, Ucarturk N (1992) The synthesis and the structure-activity relationships of some substituted benzoxazoles, oxazolo(4,5-b)pyridines, benzothiazoles and benzimidazoles as antimicrobial agents. Eur J Med Chem 27:401–406